Skip to main content

Table 2 Perioperative findings of low dose HES vs moderate dose HES group

From: Impact of 6% balanced hydroxyethyl starch following cardiopulmonary bypass on renal function: a retrospective study

Variables Low dose HES
(n = 1239)
Moderate dose HES
(n = 418)
p-value
CPB time, min 142.5 ± 65.1 150.8 ± 65.1 .02
ACC time, min 92.4 ± 48.0 97.9 ± 48.4 .05
Operation    .23
 Valve 789 (63.6) 279 (66.5)  
 CABG 88 (7.1) 20 (4.7)  
 Valve + CABG 43 (3.4) 15 (3.5)  
 Aorta 171 (13.8) 65 (15.5)  
 Others 148 (11.9) 39 (9.3)  
Crystalloid administration
 Saline, L 0.9 ± 1.0 0.8 ± 0.2 .76
 Balanced, L 3.1 ± 0.7 3.0 ± 0.8 .68
6% HES
 670/0.75, L 0.21 ± 0.2 0.8 ± 0.3 < .001
 670/0.75, ml/kg 3.9 ± 4.2 14.5 ± 4.9 < .001
 130/0.4, L 0.4 ± 0.1 0.6 ± 0.2 < .001
 130/0.4, ml/kg 7.8 ± 2.4 11.4 ± 5.3 < .001
Transfusion
 Red blood cell, L 0.9 ± 1.7 1.1 ± 1.6 .009
 Fresh frozen plasma, L 0.6 ± 1.4 0.6 ± 1.4 .24
 Cryoprecipitate, L 0.9 ± 1.9 1.3 ± 2.0 < .001
 Platelet concentrate, L 0.9 ± 2.5 1.0 ± 2.9 .15
  1. Results are presented as mean ± standard deviation or number (percentage). HES Hydroxyethyl starch; CPB Cardiopulmonary bypass; ACC Aorta cross-clamp; CABG Coronary artery bypass graft